Targets › SOX2
2 programs from 2 companies in 6 trials: 4 Phase 2, 2 Phase 1; Oncology, Ophthalmology; next expected readout Apr 2027.
Transcription factor that forms a trimeric complex with OCT4 on DNA and controls the expression of a number of genes involved in embryonic development such as YES1, FGF4, UTF1 and ZFP206 (By similarity). Binds to the proximal enhancer region of NANOG (By similarity). (UniProt, P48431)
Open in Phaseline: the race on SOX2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Washington | CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine Plasmid DNA vaccine encoding multiple tumor-associated antigens (CD105/ENG, Yb-1/YBX1, SOX | ENG, YBX1, SOX2, CDH3, MDM2, CD105, YB1 | Phase 2 | Anatomic Stage IV Breast Cancer AJCC v8; Lung Non-Small Cell Carcinoma; Anatomic Stage IB Breast Cancer AJCC v8; HER2 Negative Breast Carcinoma | Apr 2027 |
| Life Biosciences | ER-100 AAV-based epigenetic therapy delivering OSK transcription factors (OCT4, SOX2, KLF4) via i | OCT4, SOX2, KLF4 | Phase 1 | Open Angle Glaucoma (OAG) | May 2027 |
Anatomic Stage IV Breast Cancer AJCC v8 (2) Lung Non-Small Cell Carcinoma (1) Anatomic Stage IB Breast Cancer AJCC v8 (1) HER2 Negative Breast Carcinoma (1) Open Angle Glaucoma (OAG) (1)
mixed (1), other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.